StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Zymeworks (ZYME)

Wed, 03 Jun 2026 06:52:12 -0400

H.C. Wainwright analyst Andrew Berens reiterated a Buy rating and $46.00 price target on Zymeworks (NASDAQ: ZYME).

The analyst commented: "Zymeworks' partner, Jazz Pharmaceuticals (JAZZ: Under Review), recently announced that the results from the Phase 3 HERIZON-GEA-01 trial, which is evaluating Ziihera (zanidatamab) plus chemotherapy, with or without the PD-1 inhibitor Tevimbra (tislelizumab), for the treatment of 1L HER2+ locally advanced or metastatic gastroesophageal cancers, were published in NEJM. Consistent with data previously presented at ASCO GI 2026, both Ziihera-containing regimens delivered highly statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared with Herceptin (trastuzumab) plus chemotherapy. Median PFS

Form 4 Zymeworks Inc. For: May 13 Filed by: Schneider Paul R

Fri, 15 May 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260515/26507494.html

Form 4 Zymeworks Inc. For: May 13 Filed by: Schneider Paul R

Fri, 15 May 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260515/26507494.html

Form 3 Zymeworks Inc. For: May 13 Filed by: Schneider Paul R

Fri, 15 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260515/26507377.html

Form 3 Zymeworks Inc. For: May 13 Filed by: Schneider Paul R

Fri, 15 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260515/26507377.html

Form SCHEDULE 13G/A Zymeworks Inc. Filed by: Rubric Capital Management LP

Fri, 15 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260515/26505486.html

Form SCHEDULE 13G/A Zymeworks Inc. Filed by: Rubric Capital Management LP

Fri, 15 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260515/26505486.html

Form 8-K Zymeworks Inc. For: May 14

Thu, 14 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260514/26495656.html

Form 8-K Zymeworks Inc. For: May 14

Thu, 14 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260514/26495656.html

Zymeworks authorizes $125 million share repurchase program

Thu, 14 May 2026 16:05:14 -0400

Zymeworks Inc. (NASDAQ: ZYME) announced that its board of directors authorized a new share repurchase program allowing the company to buy back up to $125 million of its outstanding common stock. The biotechnology company also terminated its existing 2025 share repurchase program, under which it repurchased 4.2 million shares for $102.3 million at an average price of $24.36 per share.

The Vancouver-based company had approximately 73 million outstanding common shares as of May 13, 2026, according to the press release statement.

"The authorization of this 2026 share repurchase program reflects our continued focus on disciplined capital allocation and long-term value creation," said

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Thu, 14 May 2026 16:05:00 -0400

VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a 2026 share repurchase program under which the Company may repurchase up to $125.0 million of its outstanding common stock, par value $0.00001 per share. Concurrently, Zymeworks has terminated its existing 2025 share repurchase program under which the Company has repurchased 4,197,553 million shares of common stock for $102.3 million, representing an average purchase price of $24.36

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Thu, 14 May 2026 16:05:00 -0400

Zymeworks Announces Participation in Upcoming Investor Conferences

Wed, 13 May 2026 06:00:00 -0400

VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:

2026 Stifel Virtual Targeted Oncology Forum: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on May 20 at 9:00 am Eastern Time (ET) virtually.
TD Cowen 7^th Annual Oncology Innovation Summit: Zymeworks’ management will participate in a fireside chat on May 27 at 4:30 pm ET virtually.
2026 Jefferies Global Healthcare Conference:

Zymeworks Announces Participation in Upcoming Investor Conferences

Wed, 13 May 2026 06:00:00 -0400

2026 Stifel Virtual Targeted Oncology Forum: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on May 20 at 9:00 am Eastern Time (ET) virtually.
TD Cowen 7^th Annual Oncology Innovation Summit: Zymeworks’ management will participate in a fireside chat on May 27 at 4:30 pm ET virtually.
2026 Jefferies Global Healthcare Conference:

Zymeworks (ZYME) Reiterated at Market Outperform by Citizens After Q1 Results

Mon, 11 May 2026 04:19:51 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $32.00 price target on Zymeworks (NASDAQ: ZYME).

The analyst commented, "We reiterate our Market Outperform rating on Zymeworks and price target of $32 based on a discounted EPS and revenue multiple analysis. Recently, Zymeworks reported 1Q26 earnings results, highlighted recent platform progress presented at AACR, and provided updated milestones for 2026. With zanidatamab on track for potential approvals in 1L GEA, ZW191 (FRα TOPO1i ADC) and ZW251 (GPC3 TOPO1i ADC) making steady progress in early clinical development, a differentiated pan-RAS inhibitor (RASi) ADC platform garnering considerable external interest, an ongoing share

Zymeworks (ZYME) PT Raised to $34 at Wells Fargo

Fri, 08 May 2026 06:55:56 -0400

Wells Fargo analyst Eva Verdejo raised the price target on Zymeworks (NASDAQ: ZYME) to $34.00 (from $33.00) while maintaining a Overweight rating.

Zymeworks (ZYME) Misses Q1 EPS by 59c

Thu, 07 May 2026 16:41:54 -0400

Zymeworks (NASDAQ: ZYME) reported Q1 EPS of ($0.59).

For earnings history and earnings-related data on Zymeworks (ZYME) click here.

Form 10-Q Zymeworks Inc. For: Mar 31

Thu, 07 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260507/26453633.html

Form 10-Q Zymeworks Inc. For: Mar 31

Thu, 07 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260507/26453633.html

Form 8-K Zymeworks Inc. For: May 07

Thu, 07 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260507/26453294.html

Form 8-K Zymeworks Inc. For: May 07

Thu, 07 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260507/26453294.html

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Thu, 07 May 2026 16:05:00 -0400

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026
China’s NMPA has accepted the sBLA for zanidatamab; the U.S. FDA has granted Breakthrough Therapy Designation to zanidatamab in combination with fluoropyrimidine- and platinum-based chemotherapy (±) TEVIMBRA, for this indication.
Presented new data from our Phase 1 trial of ZW191 at AACR, continuing to support best-in-class potential in ovarian and endometrial cancers
Presented on emerging RAS inhibitor antibody-drug conjugate platform at AACR
$95.8 million utilized for share repurchases

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Thu, 07 May 2026 16:05:00 -0400

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026
China’s NMPA has accepted the sBLA for zanidatamab; the U.S. FDA has granted Breakthrough Therapy Designation to zanidatamab in combination with fluoropyrimidine- and platinum-based chemotherapy (±) TEVIMBRA, for this indication.
Presented new data from our Phase 1 trial of ZW191 at AACR, continuing to support best-in-class potential in ovarian and endometrial cancers
Presented on emerging RAS inhibitor antibody-drug conjugate platform at AACR
$95.8 million utilized for share repurchases

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Thu, 07 May 2026 16:05:00 -0400

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026
China’s NMPA has accepted the sBLA for zanidatamab; the U.S. FDA has granted Breakthrough Therapy Designation to zanidatamab in combination with fluoropyrimidine- and platinum-based chemotherapy (±) TEVIMBRA, for this indication.
Presented new data from our Phase 1 trial of ZW191 at AACR, continuing to support best-in-class potential in ovarian and endometrial cancers
Presented on emerging RAS inhibitor antibody-drug conjugate platform at AACR
$95.8 million utilized for share repurchases

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Thu, 07 May 2026 16:05:00 -0400

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026
China’s NMPA has accepted the sBLA for zanidatamab; the U.S. FDA has granted Breakthrough Therapy Designation to zanidatamab in combination with fluoropyrimidine- and platinum-based chemotherapy (±) TEVIMBRA, for this indication.
Presented new data from our Phase 1 trial of ZW191 at AACR, continuing to support best-in-class potential in ovarian and endometrial cancers
Presented on emerging RAS inhibitor antibody-drug conjugate platform at AACR
$95.8 million utilized for share repurchases